ATE141051T1 - Verwendung von melatonin zur herstellung eines arzneimittels zur behandlung der gutartigen prostatahyperplasie - Google Patents

Verwendung von melatonin zur herstellung eines arzneimittels zur behandlung der gutartigen prostatahyperplasie

Info

Publication number: ATE141051T1
Authority: AT; Austria
Prior art keywords: melatonin; treatment; beneficient; production; bph
Prior art date: 1992-04-07

Application number

AT93302513T

Other languages

English (en)

Inventor

Nava Zisapel

Original Assignee

Neurim Pharma 1991

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-04-07

Filing date

1993-03-31

Publication date

1996-08-15

1993-03-31 Application filed by Neurim Pharma 1991 filed Critical Neurim Pharma 1991

1996-08-15 Application granted granted Critical

1996-08-15 Publication of ATE141051T1 publication Critical patent/ATE141051T1/de

Links

YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 title abstract 4
229960003987 melatonin Drugs 0.000 title abstract 4
DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 title abstract 4
238000004519 manufacturing process Methods 0.000 title abstract 2
206010020718 hyperplasia Diseases 0.000 title 1
229940126601 medicinal product Drugs 0.000 title 1
210000002307 prostate Anatomy 0.000 title 1
206010004446 Benign prostatic hyperplasia Diseases 0.000 abstract 4
208000004403 Prostatic Hyperplasia Diseases 0.000 abstract 4
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 abstract 2
239000003814 drug Substances 0.000 abstract 2
102000001419 Melatonin receptor Human genes 0.000 abstract 1
108050009605 Melatonin receptor Proteins 0.000 abstract 1
239000002671 adjuvant Substances 0.000 abstract 1
230000002280 anti-androgenic effect Effects 0.000 abstract 1
229940046836 anti-estrogen Drugs 0.000 abstract 1
230000001833 anti-estrogenic effect Effects 0.000 abstract 1
239000000051 antiandrogen Substances 0.000 abstract 1
229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 abstract 1
239000003085 diluting agent Substances 0.000 abstract 1
239000000328 estrogen antagonist Substances 0.000 abstract 1
239000000122 growth hormone Substances 0.000 abstract 1
239000003966 growth inhibitor Substances 0.000 abstract 1
239000003607 modifier Substances 0.000 abstract 1
ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 abstract 1
229960004535 oxazepam Drugs 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
229960003604 testosterone Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT93302513T 1992-04-07 1993-03-31 Verwendung von melatonin zur herstellung eines arzneimittels zur behandlung der gutartigen prostatahyperplasie ATE141051T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US86468492A	1992-04-07	1992-04-07

Publications (1)

Publication Number	Publication Date
ATE141051T1 true ATE141051T1 (de)	1996-08-15

Family

ID=25343832

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT93302513T ATE141051T1 (de)	1992-04-07	1993-03-31	Verwendung von melatonin zur herstellung eines arzneimittels zur behandlung der gutartigen prostatahyperplasie

Country Status (11)

Country	Link
US (2)	US5750557A (de)
EP (1)	EP0565296B1 (de)
JP (1)	JPH0640939A (de)
AT (1)	ATE141051T1 (de)
DE (1)	DE69303919T2 (de)
DK (1)	DK0565296T3 (de)
ES (1)	ES2090861T3 (de)
GR (1)	GR3021258T3 (de)
HK (1)	HK1006681A1 (de)
IL (1)	IL105240A (de)
SG (1)	SG41955A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH09511334A (ja) *	1994-03-30	1997-11-11	チバ−ガイギーアクチェンゲゼルシャフト	Ｒｚｒ受容体ファミリーを用いるスクリーニング方法
EP0748627A3 (de) *	1995-06-14	1997-05-21	Lilly Co Eli	Melatoninagonisten zur Behandlung von gutartigen Hyperplasieformen der Prostata
NZ500217A (en) *	1997-04-07	2001-11-30	American Home Prod	Estra-5(10), 7-dienes for treating estrogen deficiency, osteoporosis and free radical induced disease states
IL150190A0 (en) *	2000-01-05	2002-12-01	Neurim Pharma 1991	Method and formulation for treating resistance to antihypertensives and related conditions
RU2221567C2 (ru) *	2000-08-25	2004-01-20	Санкт-Петербургская медицинская академия последипломного образования	Способ нормализации уровней клеточных факторов роста у мужчин с возрастным андрогенным дефицитом
IL144900A (en) *	2001-08-14	2013-12-31	Neurim Pharma 1991	Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
TWI271402B (en) *	2002-10-15	2007-01-21	Tanabe Seiyaku Co	Large conductance calcium-activated K channel opener
IL155666A (en) *	2003-04-29	2013-12-31	Neurim Pharma 1991	Insomnia treatment
US9119846B2 (en)	2003-04-29	2015-09-01	Neurim Pharmaceuticals (1991) Ltd.	Method and composition for enhancing cognition in alzheimer's patients
MXPA06009377A (es) *	2004-02-20	2007-03-07	Lifescape Biosciences Inc	Composiciones y metodos para regulacion del sueno.
WO2008116004A2 (en)	2007-03-19	2008-09-25	Vita Sciences, Llc	Transdermal patch and method for delivery of vitamin b12
DK3337462T3 (da)	2016-10-31	2020-10-12	Neurim Pharma 1991	Melatonin-minitabletter og fremgangsmåde til fremstilling heraf
US10849856B2 (en)	2016-10-31	2020-12-01	Neurim Pharmaceuticals Ltd.	Melatonin mini-tablets and method of manufacturing the same
CN114982720B (zh) *	2022-07-26	2024-02-13	贵州省人民医院	一种建立小鼠或大鼠雌雄激素失调型前列腺增生模型的方法
US12274680B2 (en)	2022-09-13	2025-04-15	II George William Creasy	Treatment of benign prostatic hypertrophy with capsinoids

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4600723A (en) *	1983-05-18	1986-07-15	Monash University	Method for minimizing disturbances in circadian rhythms of bodily performance and function
US4654361A (en) *	1986-01-27	1987-03-31	State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University	Method of lowering intraocular pressure using melatonin
WO1988006009A1 (en) *	1987-02-13	1988-08-25	Maurizio Graziosi	System for making atoxic the shoe bottoms
US4855305A (en) *	1987-03-23	1989-08-08	Applied Medical Research	Compositions and methods of effecting contraception utilizing melatonin
GB8727099D0 (en) *	1987-11-19	1987-12-23	Cellena Cell Eng A G	Compositions containing melantonin/homologues
US4945103A (en) *	1989-01-17	1990-07-31	Michael Cohen	Method of treating pre-menstrual syndrome
IN171596B (de)	1989-06-27	1992-11-21	Cohen Michael
DE69229490T2 (de)	1991-05-09	2000-02-17	Neurim Pharmaceuticals (1991) Ltd., Tel Aviv	Melatonin enthaltende Arzneimittel
US5196435A (en) *	1991-11-21	1993-03-23	Eli Lilly And Company	Melatonin derivatives and combinations with antiestrogen compounds for treating mammalian breast carcinoma

1993
- 1993-03-31 DK DK93302513.2T patent/DK0565296T3/da active
- 1993-03-31 AT AT93302513T patent/ATE141051T1/de not_active IP Right Cessation
- 1993-03-31 ES ES93302513T patent/ES2090861T3/es not_active Expired - Lifetime
- 1993-03-31 IL IL10524093A patent/IL105240A/en not_active IP Right Cessation
- 1993-03-31 DE DE69303919T patent/DE69303919T2/de not_active Expired - Fee Related
- 1993-03-31 SG SG1995002001A patent/SG41955A1/en unknown
- 1993-03-31 EP EP93302513A patent/EP0565296B1/de not_active Expired - Lifetime
- 1993-04-07 JP JP5080753A patent/JPH0640939A/ja active Pending
- 1993-08-24 US US08/111,014 patent/US5750557A/en not_active Expired - Fee Related
1996
- 1996-10-04 GR GR960402609T patent/GR3021258T3/el unknown
1997
- 1997-11-24 US US08/976,508 patent/US6048888A/en not_active Expired - Fee Related
1998
- 1998-06-23 HK HK98106095A patent/HK1006681A1/en not_active IP Right Cessation

Also Published As

Publication number	Publication date
EP0565296B1 (de)	1996-08-07
JPH0640939A (ja)	1994-02-15
DK0565296T3 (da)	1996-12-09
EP0565296A1 (de)	1993-10-13
HK1006681A1 (en)	1999-03-12
ES2090861T3 (es)	1996-10-16
IL105240A (en)	1999-04-11
IL105240A0 (en)	1993-07-08
SG41955A1 (en)	1997-08-15
GR3021258T3 (en)	1997-01-31
US6048888A (en)	2000-04-11
US5750557A (en)	1998-05-12
DE69303919T2 (de)	1997-01-30
DE69303919D1 (de)	1996-09-12

Similar Documents

Publication	Publication Date	Title
DE69303919D1 (de)	1996-09-12	Verwendung von Melatonin zur Herstellung eines Arzneimittels zur Behandlung der gutartigen Prostatahyperplasie
HUT60138A (en)	1992-08-28	Process for producing combination compositions suitable for preventing and/or treating benign prostatic hyperplasia
ATE430568T1 (de)	2009-05-15	Verfahren und zusammensetzungen zur vorbeugung oder behandlung von atherosclerose, restenose und zusammenhängenden erkrankungen
ATE198706T1 (de)	2001-02-15	Polyamin-verbindungen zur behandlung von proliferativer erkrankungen
ATE319447T1 (de)	2006-03-15	Pharmazeutische zubereitungen die clavulansäure oder derivate enthalten zur behandlund von neurologischen störungen
DE69424537D1 (de)	2000-06-21	Therapeutischer wirkstoff zur behandlung von melanomen
TR200001752T2 (tr)	2000-12-21	Entegrin reseptör antagonistleri
EP1955700A3 (de)	2008-12-10	Therapeutische Behandlung androgenrezeptorbedingter Leiden
DE59508360D1 (de)	2000-06-21	Liposomal verkapseltes taxol, seine herstellung und seine verwendung
DE69310634D1 (de)	1997-06-19	Verwendung von Taxol zur Herstellung eines Arzneimittels zur Behandlung von Krebs
ATE141505T1 (de)	1996-09-15	Verwendung von 3-guanidinopropionsäure zur herstellung eines medikaments zur behandlung und prävention von fettsucht
DE69713273D1 (de)	2002-07-18	Verwendung von 3,4-Diphenylchromanen zur Herstellung eines Arzneimittels zur Behandlung bzw. Vorbeugung des Prostatakarzinoms
ATE361075T1 (de)	2007-05-15	Pharmazeutische kombination zur behandlung von benigner prostatahyperplasie oder zur langzeitvorbeugung von akuter harnzurückhaltung
DE3685052D1 (de)	1992-06-04	Linolensaeuren enthaltende pharmazeutische und diaet-zusammensetzungen zur behandlung von gutartiger prostatahypertrophie.
RU94040886A (ru)	1996-09-20	Применение производных мелатонина для лечения нарушений сна, фармацевтическая композиция
DE69924483D1 (de)	2005-05-04	Kombinationstherapie zur behandlung von tumoren
RU94041028A (ru)	1996-09-20	Применение производных мелатонина для лечения десинхронизационных нарушений, фармацевтическая композиция
ATE192929T1 (de)	2000-06-15	Verwendung von dimeticon zur herstellung eines arzneimittels zur behandlung von aphthen und stomatitis
DE59101818D1 (de)	1994-07-14	Arzneimittelzubereitung, enthaltend Stigmasta-4-en-3-on sowie deren Verwendung.
BR9203266A (pt)	1993-04-06	Composto,formulacao farmaceutica,processo para inibir 5alfa-reductase,processos para tratar hiperplasia benigna da prostata,seborreia e alopecia androgenica
DE69424415D1 (de)	2000-06-15	Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung parkinsonscher krankheit
ATE91080T1 (de)	1993-07-15	Praeparat zum vorbeugen gegen knochenschwund und zur behandlung von knochenschwund.
HUP9901139A3 (en)	2000-01-28	Use of melatonin agonists for producing pharmaceutical compositions suitable for treating benign prostatic hyperplasia
MX9710075A (es)	1998-03-29	Antagonistas melatonina para el tratamiento en la hiperplasia prostatica benigna.
UA30798A (uk)	2000-12-15	Спосіб пролонгованої терапії онкологічних хворих

Legal Events

Date	Code	Title	Description
1997-02-15	UEP	Publication of translation of european patent specification
2005-12-15	REN	Ceased due to non-payment of the annual fee